Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756728 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
A Phase 1 study, sponsored by BioInvent International AB.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02756728 is a Phase 1 study that was terminated before completion, run by BioInvent International AB. The registered enrollment target is 5 participants.
The verdict
NCT02756728, a Phase 1 study, was terminated before completion, sponsored by BioInvent International AB.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.
Interventions
- BIOLOGICAL BI-505
- OTHER High dose melphalan
- OTHER Autologous stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756728
The ClinicalTrials.gov registry entry for NCT02756728 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioInvent International AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BI-505 is the first listed.
NCT02756728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756728 about?
NCT02756728 is a clinical study titled "A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma". The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.
What is the current status of trial NCT02756728?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2016-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02756728?
The interventions under investigation include: BI-505 (BIOLOGICAL), High dose melphalan (OTHER), Autologous stem cell transplantation (OTHER).
Who is sponsoring clinical trial NCT02756728?
This trial is sponsored by BioInvent International AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.